Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 501 - 550 out of 6,026

Document Document Title
WO/2008/030618A1
The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables Q, L1, ℗, L2, M, X, L3, and A are provided h...  
WO/2008/023720A1
[PROBLEMS] To provide a compound which can be used for the treatment of a disease associated with fatty acid amide hydrolase (FAAH), particularly frequent urination, urinary incontinence and/or overactive bladder. [MEANS FOR SOLVING PROB...  
WO/2007/090617A3
This invention provides specifically substituted 1,2,4-thiadiazole derivatives for use in the treatment of an α-synucleopathy such as Parkinson's disease, diffuse Lewy body disease, traumatic brain injury, amyotrophic lateral sclerosis,...  
WO/2008/022771A1
The present invention, relates to compounds of formula (I), wherein A is hydrogen or (C1-4)alkyl, R1 is a group Y-R2, Y is not present or is (C1-4)alkylene, which alkylene optionally is substituted, e.g. one or morefold, by halogen, such...  
WO/2008/023157A1
A compound of formula (I): Formula (I) having M3 receptor- antagonist activity or having both muscarinic receptor antagonist and β2-agonist activity; a composition comprising such a compound; the use of such a compound in therapy (such ...  
WO/2008/021849A2
Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.  
WO/2008/020256A2
(I) The present invention is related to new 3,4-dihydroberizo[1,2,3]thiadiazine-1,1-dioxide derivatives of the Formula (I), medicaments containing said new compounds, process for the preparation thereof and the use of said derivatives in...  
WO/2007/103456A3
This invention relates to piperazine and piperidine biaryl compounds of Formula (I) or a pharmaceutically acceptable prodrug, salt, polymorph, solvate, enantiomer, diastereomer, racemate, mixture of stereoisomers thereof, or derivative t...  
WO/2008/020255A1
(I) The present invention relates to new benzo[1,2,3]thiadiazine-1,1 dioxide derivatives of the general Formula (I), medicament containing such compounds and the use thereof in the medicin Benzo[1,2,3]thiadiazine-1,1-dioxide derivatives ...  
WO/2008/017164A1
The invention is directed to thiophenecarboxamide derivatives of formulae I and II as EP4 receptor ligands, antagonists or agonists, useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoar...  
WO/2008/019090A2
The invention provides compounds formulae I-III, their preparation, and their use as pharmaceutically active immunosuppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an act...  
WO/2008/016692A2
The invention provides compounds formula I, their preparation, and their use as pharmaceutically active immunosuppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activate...  
WO/2008/016674A1
The invention provides compounds of formula I and formula II, their preparation, a their use as pharmaceutically active immunosuppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated ...  
WO/2008/014199A2
Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are ...  
WO/2008/009734A1
The invention relates to novel macrocyclic compounds of the formula (I), in which all of the variables are as defined in the specification, in free base form or in acid addition salt form, to their preparation, to their use as medicament...  
WO/2008/007780A1
Disclosed is a pentadienamide derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof or the like. (I) wherein R1 represents a substituted or unsubstituted aryl or a substituted or unsubstituted aromatic h...  
WO/2008/008394A1
Disclosed herein is a novel succinate salt of tizanidine with improved properties. Also described herein are novel pharmaceutical compositions comprising tizanidine succinate salt, methods of making, and related methods of treatment.  
WO/2008/000408A1
The invention relates to compounds of the formula (I) in which R1, R2, A, B, X and Y have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors...  
WO/2008/000438A1
A compound of formula (I), wherein A1, A2, A3, A4, R1 , R2, G1, G2, Q1 and Q2 are as defined in claim 1; or salts or N-oxides thereof. Furthermore, the present invention relates to processes and intermediates for preparing compounds of f...  
WO/2007/140233A1
Compounds that inhibit Plk1, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.  
WO/2007/136051A1
This invention provides an optical recording material, which can solve a problem of recording density in an optical recording medium, and an optical recording medium using the optical recording material. The optical recording material co...  
WO/2007/092190A3
The present invention relates to compounds which modulate the activity of the SlPl receptor, the use of these compounds for treating conditions associated with signaling through the SlPl receptor, and pharmaceutical compositions comprisi...  
WO/2005/037805A3
The present invention relates to a 1,2,4-thiadiazole compound of the formula (I) represented by the formula (1): wherein R¿1? represents C3-C7 alkynyl and X represents C4-C7 straight alkylene optionally substituted with one to four of R...  
WO/2007/056469A3
Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.  
WO/2007/095050A3
The present invention is directed to modulators of indoleamine 2,3-dioxygenase (IDO), as well as pharmaceutical compositions containing the same and methods for the treatment of IDO-associated diseases.  
WO/2006/122319A3
Compounds, pharmaceutical compositions, kits and methods are provided for use with HDAC that comprise a compound selected from the group consisting of : formula (I) and formula (II) wherein the variables are as defined herein.  
WO/2007/067615A3
Compounds of the formula are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inh...  
WO/2007/073503A3
Novel non-steroidal compounds are provided that are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases having ...  
WO/2007/123718A1
1-Heterocyclylamino-2-hydroxy-3-amino-ω-arylalkanes of formula (I) and the salts thereof have renin-inhibiting properties and can be used as antihypertensive, medicinally active ingredients.  
WO/2007/054257A3
The present invention makes reference to new indene derivatives with general formula (I), as well as to their preparation procedures, their application as medicament and the pharmaceutical compositions containing them. The new compounds ...  
WO/2007/116374A1
The invention relates to sulfonamide compounds of formula (I), where A, B, R3 and R4 are as defined in the claims, and their use as orexin receptor antagonists in the prevention and treatment of eating and drinking disorders, all types o...  
WO/2007/117180A1
The invention relates to novel azaheterocycles of interest as potential physiologically active substances (agonists, antagonists, receptor modulators, ferment inhibitors, oncolytics, antibacterial and antiparasitic agent etc.), to combin...  
WO/2007/115058A2
Compounds of the formula (I) are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as...  
WO/2007/095050A2
The present invention is directed to modulators of indoleamine 2,3-dioxygenase (IDO), as well as pharmaceutical compositions containing the same and methods for the treatment of IDO-associated diseases.  
WO/2007/090617A2
This invention provides specifically substituted 1,2,4-thiadiazole derivatives for use in the treatment of an α-synucleopathy such as Parkinson's disease, diffuse Lewy body disease, traumatic brain injury, amyotrophic lateral sclerosis,...  
WO/2007/092190A2
The present invention relates to compounds which modulate the activity of the SlPl receptor, the use of these compounds for treating conditions associated with signaling through the SlPl receptor, and pharmaceutical compositions comprisi...  
WO/2007/087906A1
The present invention relates to N-cycloalkyl-benzyl-amide derivatives of formula (I) wherein the substituents are as in the description, their process of preparation, their use as fungicide active agents, particularly in the form of fun...  
WO/2007/086584A1
Disclosed is a compound which can inhibit both of FabI and FabK which are fatty acid synthases to show a wide antibacterial spectrum including Streptococcus pneumoniae, Pseudomonas aeruginosa and Enterococcus faecalis, and therefore can ...  
WO2007073503A8
Novel non-steroidal compounds are provided that are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-?B activity including obesity, diabetes, inflammatory and immune diseases having t...  
WO/2007/082471A1
Anti-infective compound, preparation method thereof and use thereof. The present invention disclosed a crystal of 6-fluoro-1-methyl-4-oxo-7-(1-piperazinyl)-4H-[1,3]thiazeto[3 ,2-a]quinoline-3-carboxylic acid (II) methanesulfonate, which ...  
WO/2007/082472A1
Anti-infective quinolone compound, preparation method thereof and use thereof. The present invention disclosed the pharmaceutically acceptable salt of 6-fluoro-1-methyl-4-oxo-7- (1- piperazinyl) - 4H -[1,3]thiazeto[3,2-a]quinoline-3-carb...  
WO/2007/079959A1
The invention relates to the substituted propiolic acid amides of general formula (I), to methods for producing them, to drugs containing said compounds and to the use thereof for producing drugs.  
WO/2007/019078A3
The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer'...  
WO/2007/074171A1
Methods for the synthesis of various novel substituted dipeptide derived nitrogen-containing heterocyclic compounds (I) and their pharmaceutically acceptable salt derivatives are provided. The compounds of the invention are claimed and a...  
WO/2006/044860A3
The invention relates to thiadiazole compounds useful for treating diseases mediated by protein kinase B (PKB). The invention also relates to the therapeutic use of such thiadiazole compounds and compositions thereof in treating disease ...  
WO/2007/072763A1
Disclosed are a novel cyclic fluorosulfonyl imide salt and an electrolyte. Specifically disclosed are a compound (1) shown below and an electrolyte containing a compound (1m) shown below. In this connection, n represents 1, 2, 3 or 4; [M...  
WO/2007/071900A1
Compounds of formula I: wherein R1, R2, R3, R4, m, R5, R6, n and Y are as defined in claim 1; or N-oxides, salts and optical isomers thereof. Furthermore, the present invention relates to processes for preparing compounds of formula (I),...  
WO/2007/073503A2
Novel non-steroidal compounds are provided that are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases having ...  
WO/2007/067615A2
Compounds of the formula are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inh...  
WO/2007/067613A1
Compounds of the formula (I) are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as...  

Matches 501 - 550 out of 6,026